secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2024-07-22T23:59:59+00:00
Accession:  0001493152-24-028637
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.03, 3.02, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hepion Pharmaceuticals enters definitive merger agreement with Pharma Two B Ltd., expects Q4 2024 close
--------------------------------------------------------------------------------

- Hepion will merge with Pharma Two B Ltd.; existing Hepion shareholders receive ordinary shares of Parent.
- Concurrent $2.9M note sale (SPA) at 116% of principal; purchasers also receive up to 19.99% of HEPA outstanding shares.
- Closing expected Q4 2024, subject to stockholder approvals, Nasdaq listing, IIA approval, and at least $8.6M cash from SPA.
- Certain Hepion stockholders entered support agreements (covering ~0.025% of shares) and 180-day lock-up agreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000149315224028637/0001493152-24-028637-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000149315224028637/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-028637

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer